fludarabin phosphat synthet purin antimetabolit signific activ lymphoid malign fludarabin phosphat deriv vidarabin ara-a advantag resist deamin adenosin deaminas ada solubl mechan cytotox action compound metabol convers activ triphosph fludarabin phosphat substanti activ lymphoid malign chronic lymphocyt leukemia cll low-grad non-hodgkin lymphoma nhl single-ag activ cll compar convent combin regimen activ hodgkin diseas mycosi fungoid macroglobulinemia suggest clinic trial hairi cell leukemia prolymphocyt leukemia untreat myeloma compound activ common solid tumor earli clinic trial signific myelosuppress potenti sever neurotox toxic low-dos schedul transient revers myelosuppress nausea vomit diarrhea somnolence/fatigu elev liver enzym serum creatinin possibl pulmonari toxic sever patient low-dos fludarabin phosphat administr appear safe neglig risk sever neurotox single-ag activ toler food drug administr group design drug treatment patient refractori cll clinic trial use fludarabin phosphat combin regimen impact natur histori lymphoid malign fludarabin phosphat pivot role manag cll low-grad nhl 